LIFE Stock Overview
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
aTyr Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.37 |
| 52 Week High | US$6.62 |
| 52 Week Low | US$2.00 |
| Beta | 1.25 |
| 1 Month Change | 8.22% |
| 3 Month Change | -4.82% |
| 1 Year Change | -58.35% |
| 3 Year Change | -55.87% |
| 5 Year Change | -94.79% |
| Change since IPO | -99.12% |
Recent News & Updates
Recent updates
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09
Shareholder Returns
| LIFE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.7% | 0.8% | 2.8% |
| 1Y | -58.3% | 7.1% | -9.2% |
Return vs Industry: LIFE underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: LIFE underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| LIFE volatility | |
|---|---|
| LIFE Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LIFE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: LIFE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 51 | Sanjay Shukla | https://www.atyrpharma.com |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors.
aTyr Pharma, Inc. Fundamentals Summary
| LIFE fundamental statistics | |
|---|---|
| Market Cap | US$68.75m |
| Earnings (TTM) | -US$46.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs LIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIFE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$33.85m |
| Gross Profit | -US$33.85m |
| Other Expenses | US$12.52m |
| Earnings | -US$46.38m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LIFE perform over the long term?
See historical performance and comparison